Triple-Negative Breast Cancer | Topics

Eganelisib Combination Therapies Demonstrate Promising Survival Benefit in Advanced Urothelial Carcinoma and TNBC
July 28, 2021

Novel eganelisib shows survival-extending potential in patients with triple-negative breast and bladder cancers.

FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
July 27, 2021

Based on results of the KEYNOTE-522 trial, the FDA approved pembrolizumab, the first immunotherapy for this indication, plus chemotherapy as neoadjuvant treatment for patients with early-stage triple-negative breast cancer.

Leronlimab Plus Carboplatin Appears to Yield Survival Benefit in Metastatic Triple-Negative Breast Cancer
July 19, 2021

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit.